SGLT2 Inhibitors
8
2
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
63%
5 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF
Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients
Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients
Efficacy of SGLT2 Inhibitors in Adults With Sepsis
SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients
SGLT2 Inhibitors and Reducing the Risk of Cancers Among Diabetics , an Observational Study
The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products